Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States
The aim of this study was to systematically evaluate state Medicaid policies for the treatment
of hepatitis C virus (HCV) infection with sofosbuvir in the United States. Medicaid …
of hepatitis C virus (HCV) infection with sofosbuvir in the United States. Medicaid …
Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection
JJ Feld, IM Jacobson, C Hézode… - … England Journal of …, 2015 - Mass Medical Soc
Background A simple treatment regimen that is effective in a broad range of patients who are
chronically infected with the hepatitis C virus (HCV) remains an unmet medical need …
chronically infected with the hepatitis C virus (HCV) remains an unmet medical need …
Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States
RJ Wong, M Aguilar, R Cheung, RB Perumpail… - Gastroenterology, 2015 - Elsevier
Background & Aims Nonalcoholic steatohepatitis (NASH) has been predicted to become the
leading indication for liver transplantation (LT) in the United States. However, few studies …
leading indication for liver transplantation (LT) in the United States. However, few studies …
Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a …
S Zeuzem, R Ghalib, KR Reddy, PJ Pockros… - Annals of internal …, 2015 - acpjournals.org
Background: Novel interferon-and ribavirin-free regimens are needed to treat hepatitis C
virus (HCV) infection. Objective: To evaluate the safety and efficacy of grazoprevir (NS3/4A …
virus (HCV) infection. Objective: To evaluate the safety and efficacy of grazoprevir (NS3/4A …
[HTML][HTML] CD39 Expression Identifies Terminally Exhausted CD8+ T Cells
Exhausted T cells express multiple co-inhibitory molecules that impair their function and limit
immunity to chronic viral infection. Defining novel markers of exhaustion is important both for …
immunity to chronic viral infection. Defining novel markers of exhaustion is important both for …
Recommendations for the management of hepatitis C virus infection among people who inject drugs
In high income countries, the majority of new and existing hepatitis C virus (HCV) infections
occur among people who inject drugs (PWID). In many low and middle income countries …
occur among people who inject drugs (PWID). In many low and middle income countries …
[HTML][HTML] Hepatitis C virus: A global view
AA Mohamed, TA Elbedewy, M El-Serafy… - World journal of …, 2015 - ncbi.nlm.nih.gov
Hepatitis C virus (HCV) is a global challenge; 130-175 million are chronically infected. Over
350000 die each year from HCV. Chronic HCV is the primary cause of cirrhosis …
350000 die each year from HCV. Chronic HCV is the primary cause of cirrhosis …
Hepatitis C virus therapeutic development: in pursuit of “perfectovir”
The next decade will be a crucial period in the public health response to hepatitis C virus
(HCV) infection. The rapid development of direct-acting antiviral (DAA) therapy for HCV …
(HCV) infection. The rapid development of direct-acting antiviral (DAA) therapy for HCV …
Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial
GT Everson, WJ Towner, MN Davis… - Annals of internal …, 2015 - acpjournals.org
This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: Effective, pangenotypic treatments for hepatitis C virus (HCV) …
Supplement. Background: Effective, pangenotypic treatments for hepatitis C virus (HCV) …